Efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir in non-cirrhotic Asian patients with genotype 1b chronic hepatitis C virus infection: ONYX-I post-treatment week 24 results
单位：[1]Peking Univ, Peoples Hosp, Beijing, Peoples R China[2]Nanfang Hosp, Guangzhou, Guangdong, Peoples R China[3]AbbVie Inc, N Chicago, IL USA[4]Pusan Natl Univ, Dept Internal Med, Coll Med, Busan, South Korea[5]Pusan Natl Univ Hosp, Med Res Inst, Busan, South Korea[6]Taipei Vet Gen Hosp, Taipei, Taiwan[7]Capital Med Univ, Beijing YouAn Hosp, Beijing, Peoples R China[8]Pusan Natl Univ, Yangsan Hosp, Yangsan, South Korea[9]Capital Med Univ, Beijing Di Tan Hosp, Beijing, Peoples R China[10]Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China江苏省人民医院[11]Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China首都医科大学附属北京友谊医院[12]Kaohsiung Med Univ, Kaohsiung, Taiwan
第一作者单位：[1]Peking Univ, Peoples Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Wei L.,Hou J.,Luo Y.,et al.Efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir in non-cirrhotic Asian patients with genotype 1b chronic hepatitis C virus infection: ONYX-I post-treatment week 24 results[J].JOURNAL of HEPATOLOGY.2017,66(1):S532-S532.
APA：
Wei, L.,Hou, J.,Luo, Y.,Heo, J.,Chu, C. -J....&Chuang, W. -L..(2017).Efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir in non-cirrhotic Asian patients with genotype 1b chronic hepatitis C virus infection: ONYX-I post-treatment week 24 results.JOURNAL of HEPATOLOGY,66,(1)
MLA：
Wei, L.,et al."Efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir in non-cirrhotic Asian patients with genotype 1b chronic hepatitis C virus infection: ONYX-I post-treatment week 24 results".JOURNAL of HEPATOLOGY 66..1(2017):S532-S532
医学